IntraBio Inc

IntraBio Inc. is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for neurodegenerative diseases with high unmet medical needs. Their expertise lies in modulating lysosomal function and intracellular calcium signaling, building on decades of research from the University of Oxford and University of Munich. They have a strong track record of drug development and commercialization, with a focus on orphan indications where there are currently no FDA-approved therapies, such as Niemann-Pick Disease Type C (NPC), GM2 Gangliosidosis, and Ataxia-Telangiectasia.

Their lead drug, IB1001, has shown promising results in clinical trials for NPC and is currently being developed for other rare and common neurological disorders. They have received numerous Orphan Drug Designations and Fast Track designations from the FDA and EMA, signifying the potential impact of their work on patients with rare diseases. IntraBio's commitment to delivering innovative treatments to patients as quickly as possible through comprehensive clinical trials highlights their dedication to making a difference in the lives of those affected by neurodegenerative diseases.

IntraBio Inc. is a late-stage biopharmaceutical company dedicated to discovering, developing, and commercializing therapies for neurodegenerative diseases with high unmet medical needs. Their mission is to translate research into potential treatments that significantly improve the lives of patients, caregivers, and families affected by these devastating diseases. They leverage the expertise of their scientific founders from the University of Oxford and the University of Munich, renowned experts in lysosomal function and intracellular calcium signaling, to develop innovative therapies.

IntraBio promotes a culture focused on innovation, collaboration, and patient-centricity. The company values scientific rigor and expertise, as evidenced by its founding team of renowned scientists from Oxford and Munich. This culture fosters a collaborative environment where research translates into real-world treatments, ultimately improving the lives of patients suffering from rare neurodegenerative diseases. The company's commitment to transparency and communication is demonstrated through its active engagement with patients, advocacy groups, and global health authorities.